November 25th 2024
FDA approval was granted on September 13, 2024.
November 12th 2024
September 23rd 2024
September 23rd 2024
Best Practices for Optimizing Biologic Therapy Management for Moderate to Severe Atopic Dermatitis in Children
1.5 Credits / Dermatology, Immunology
View More
The Evolving Treatment Paradigm of Demodex Blepharitis: Considerations for Pharmacists (Pharmacy Technician Cr...
1.0 Credits / Ophthalmology/Optometry, Dermatology
View More
The Evolving Treatment Paradigm of Demodex Blepharitis: Considerations for Pharmacists (Pharmacist Credit)
1.0 Credits / Ophthalmology/Optometry, Dermatology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Navigating the Complexities of Biologic Therapy for Moderate to Severe Atopic Dermatitis in Children: The Impa...
1.5 Credit / Dermatology, Immunology
View More
The Role of Daily Photoprotection and Antioxidants in Sun Protection: A Guide for Pharmacists and Pharmacy Tec...
1.0 Credit / Dermatology, OTC
View More
Understanding the Role of Ceramides in Acne Management: Opportunities to Improve Clinical Outcomes (Pharmacy T...
1.0 Credit / Dermatology, OTC
View More
Skin-Related Changes in Persons With Diabetes: Using Ceramides to Address Skin Barrier Dysfunction (Pharmacy T...
1.0 Credit / Dermatology, OTC
View More
Adjunctive Therapies in Atopic Dermatitis: Understanding the Role of the Skin Barrier and Microbiome in Diseas...
1.0 Credit / Dermatology, OTC
View More
Alleviating Patient Burden in Acne: Utilizing Ceramides to Address Skin Barrier Dysfunction (Pharmacy Technici...
0.75 Credit / Dermatology, OTC
View More
Examining Patient Burden in Atopic Dermatitis: Understanding Treatment Barriers and Optimal Use of OTC Skin Ca...
0.5 Credit / Dermatology, OTC
View More
Addressing the Challenges of Treating Moderate to Severe Atopic Dermatitis With Targeted Biologic Therapies in...
1.5 Credits / Allergy, Dermatology, Immunology
View More
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
1.5 Credits / Dermatology, Immunology
View More
Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care
1.5 Credits / Dermatology
View More
Alleviating Patient Burden in Acne: Utilizing Ceramides to Address Skin Barrier Dysfunction
0.75 Credit / Dermatology, OTC
View More
Examining Patient Burden in Atopic Dermatitis: Understanding Treatment Barriers and Optimal Use of OTC Skin Ca...
0.5 Credit / Dermatology, OTC
View More
Skin-Related Changes in Persons With Diabetes: Using Ceramides to Address Skin Barrier Dysfunction
1.0 Credit / Dermatology, OTC
View More
Adjunctive Therapies in Atopic Dermatitis: Understanding the Role of the Skin Barrier and Microbiome in Diseas...
1.0 Credit / Dermatology, OTC
View More
Understanding the Role of Ceramides in Acne Management: Opportunities to Improve Clinical Outcomes
1.0 Credit / Dermatology, OTC
View More
The Role of Daily Photoprotection and Antioxidants in Sun Protection: A Guide for Pharmacists and Pharmacy Tec...
1.0 Credit / Dermatology, OTC
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Balancing the Burden of Moderate to Severe Atopic Dermatitis in Pediatric Patients: Navigating the Use of Targ...
1.5 Credits / Dermatology, Immunology
View More
FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Atopic Dermatitis
April 29th 2024The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.
Examining the State of Benzoyl Peroxide-Containing Acne Products After Benzene Contamination
April 10th 2024Christopher Bunick, MD, PhD, FAAD, an associate professor of dermatology and a physician-scientist at the Yale School of Medicine in New Haven, Connecticut, presented updates on benzene in BPO at the 2024 American Academy of Dermatology Annual Meeting.
Roflumilast Foam 0.3% Secures Major FDA Approval to Treat Seborrheic Dermatitis
December 18th 2023The foam formulation and once-daily application of roflumilast foam 0.3%, the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades, makes it a favorable alternative to existing treatments.